Abstract
The COVID-19 pandemic places a significant stress on the viral testing capabilities of many countries. The value of rapid point-of-care (PoC) antigen tests is becoming increasingly clear, but implementing frequent large scale testing is costly. We have developed an inexpensive device for pooling swabs, extracting specimens, and detecting viral antigens with a commercial lateral flow assay detecting the nucleocapsid protein of SARS-CoV-2 as antigen. The holder of the device can be produced locally through 3D printing. The extraction and the elution can be performed with the entire set-up encapsulated in a transparent bag, minimizing the risk of infection for the operator. With 6 swabs holding approx. 0.1 mL specimen each and 0.35 mL extraction buffer, 43±6 % (n= 8) of the signal for an individual extraction of a positive control standard was obtained. Image analysis still showed a signal-to-noise ratio of ≥ 7 upon further eight-fold dilution. Our current total cost of materials is below $ 2 per tested person or 20% of our cost for an individual PoC test. These findings suggest that pooling can make frequent testing more affordable for schools, universities and other institutions, without decreasing sensitivity to an unacceptable level. Further validation of the method is required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by intramural funds. The work of the Richert Research Group on antiviral agents is supported by Volkswagen Foundation (supplement to grant Az 92 768). Neither the authors nor their institutions at any time received payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study was reviewed by the Ethics Committee (institutional review board, IRB) of the University of Konstanz, Universitaetsstrasse 10, D-78464 Konstanz, Germany. After vetting the Description of Work (DoW), the project was found to fall outside the range of projects requiring an IRB statement. For this type of project, approval by the IRB or any regulatory body is not required according to our University's and national statutes in Germany. This study was noninvasive/minimally-invasive, and other issues concerning a threat to human health, well-being and dignity (including e.g. deception protocols) have not been identified. The project obtained approval number IRB21KN003-02/w.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is being made available in the manuscript and the Supplementary files.
